TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

Continue » Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth ...

A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+ “We are pleased to have reached a ...